Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

384
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
384
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

317
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
317
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

176
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
176
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

464
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
464
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

353
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
353
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

101
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
101

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

137Cs Lake Sediment Depth Profiles and Inventories Within Four Lakes of Idaho's Sawtooth Wilderness.

Health physics·2018
Same author

241Am INGROWTH AND ITS EFFECT ON INTERNAL DOSE.

Health physics·2016
Same author

Application of NCRP 156 Wound Model and ICRP 67 Systemic Plutonium Model for Analysis of Urine Data from Simulated Wounds in Nonhuman Primates.

Health physics·2016
Same author

Plutonium-DTPA Model Application with USTUR Case 0269.

Health physics·2015
Same author

Proposed Modification to the Plutonium Systemic Model.

Health physics·2015
Same author

Selective inhibitory effects of 50-nm gold nanoparticles on mouse macrophage and spleen cells.

Journal of immunotoxicology·2015

Related Experiment Video

Updated: Apr 14, 2026

Speciation and Bioavailability Measurements of Environmental Plutonium Using Diffusion in Thin Films
12:22

Speciation and Bioavailability Measurements of Environmental Plutonium Using Diffusion in Thin Films

Published on: November 9, 2015

12.0K

Development of the Plutonium-DTPA Biokinetic Model.

Kevin Konzen1, Richard Brey

  • 1*CH2M-WG Idaho, LLC, Radiological Control, 1580 Sawtelle Street, Idaho Falls, ID 83402; †Department of Nuclear Engineering and Health Physics, Idaho State University, 921 South 8th Avenue, Stop 8060, Pocatello, ID 83209-8060.

Health Physics
|April 24, 2015
PubMed
Summary

A new biokinetic model for plutonium with diethylenetriamine pentaacetic acid (DTPA) aids in estimating radionuclide intakes after chelation treatment. This model supports effective treatment strategies for plutonium contamination, improving dosimetric assessments.

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.6K
Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain
06:31

Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain

Published on: August 8, 2019

7.8K

Related Experiment Videos

Last Updated: Apr 14, 2026

Speciation and Bioavailability Measurements of Environmental Plutonium Using Diffusion in Thin Films
12:22

Speciation and Bioavailability Measurements of Environmental Plutonium Using Diffusion in Thin Films

Published on: November 9, 2015

12.0K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.6K
Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain
06:31

Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain

Published on: August 8, 2019

7.8K

Area of Science:

  • Radiological protection
  • Biokinetics
  • Nuclear medicine

Background:

  • Estimating radionuclide intake after chelation therapy is challenging due to enhanced excretion and lack of standard biokinetic models.
  • Plutonium (Pu) contamination requires specific biokinetic considerations, especially post-chelation treatment.

Purpose of the Study:

  • To develop and present a plutonium-diethylenetriamine pentaacetic acid (Pu-DTPA) biokinetic model.
  • To supplement existing biokinetic models for dosimetric assessments of plutonium intake.
  • To evaluate and recommend effective chelation treatment strategies for plutonium exposure.

Main Methods:

  • Development of a specific biokinetic model for plutonium in conjunction with DTPA treatment.
  • Evaluation of various chelation strategies, including early and late treatment timings and frequencies.
  • Application of the Pu-DTPA model to assess treatment effectiveness and estimate initial intakes.

Main Results:

  • The Pu-DTPA biokinetic model facilitates the determination of plutonium intakes post-chelation.
  • Recommendations for effective chelation strategies include early DTPA treatment for soluble inhalations and a 3-day series for wounds.
  • Late chelation strategies showed reduced frequencies can be as effective as multiple treatments.

Conclusions:

  • The Pu-DTPA biokinetic model is a valuable tool for dosimetrists managing plutonium contamination.
  • The model aids in estimating initial transuranic radionuclide intakes and studying the impact of different chelation protocols.
  • Optimized chelation strategies can enhance the effectiveness of radionuclide decorporation therapy.